Angiozyme: a novel angiogenesis inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Angiogenesis inhibitors are crucial for cancer treatment.
• The vascular endothelial growth factor (VEGF) pathway is a key target.
• Ribozymes offer a novel approach to inhibit VEGF receptor activity.

Purpose of the Study:

• To evaluate the efficacy of ribozymes targeting VEGF receptors (Flt-1 and KDR) for cancer therapy.
• To assess the antitumor effects of the anti-Flt-1 ribozyme, Angiozyme, in preclinical models.
• To review the safety and tolerability of Angiozyme in ongoing clinical trials.

Main Methods:

• Development of catalytic RNA molecules (ribozymes) to cleave specific VEGF receptor mRNAs (Flt-1 and KDR).
• Testing of ribozymes, particularly Angiozyme, in animal tumor models.
• Conducting clinical trials (Phase II) to evaluate Angiozyme's safety and therapeutic efficacy in patients with advanced malignancy.

Main Results:

• Significant inhibition of angiogenesis was demonstrated using ribozymes targeting both Flt-1 and KDR.
• The anti-Flt-1 ribozyme, Angiozyme, exhibited the most pronounced antitumor effects in animal models.
• Preclinical studies showed no significant toxicities associated with Angiozyme.
• Preliminary clinical data indicate Angiozyme is well-tolerated with minimal side effects.

Conclusions:

• Ribozymes targeting VEGF receptors, specifically Angiozyme, represent a promising strategy for cancer treatment by inhibiting angiogenesis.
• Angiozyme has demonstrated significant antitumor activity in preclinical settings and is well-tolerated in early-stage clinical trials.
• Further Phase II trials are ongoing to confirm the therapeutic efficacy of Angiozyme in patients with advanced cancers.